Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

被引：2
|
作者：
Luster, Markus [1 ]
Schlumberger, Martin [2 ]
Pacini, Furio [3 ]
机构：
[1] Univ Ulm, Dept Nucl Med, D-89081 Ulm, Germany
[2] Inst Gustave Roussy, Dept Nucl Med & Endocrine Oncol, F-94805 Villejuif, France
[3] Univ Siena, Sect Endocrinol & Metab, Dept Internal Med, I-53100 Siena, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2009年 / 36卷 / 02期
关键词：
HORMONE WITHDRAWAL; RADIOIODINE THERAPY; MANAGEMENT; CARCINOMA; DOSIMETRY; ABLATION;
D O I：
10.1007/s00259-008-1013-9
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：329 / 330
页数：2
相关论文
共 50 条
  • [41] Differentiated Thyroid Carcinoma: Is There Any Evidence for the Use of Recombinant Human TSH in Thyroid Hormone-Secreting Metastasis? REPLY
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (08) : 1330 - 1330
  • [42] TSH Level as Predictor of Differentiated Thyroid Cancer.
    Dorange-Recton, Anne
    Illouz, Frederic
    Triau, Stephane
    Mucci-Hennekinne, Stephanie
    Bizon, Alain
    Laboureau, Sandrine
    Dubois, Severine
    Rohmer, Vincent
    Rodien, Patrice
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [43] I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal
    Hong, Chae Moon
    Kim, Choon-Young
    Son, Seung Hyun
    Jung, Ji-hoon
    Lee, Chang-Hee
    Jeong, Ju Hye
    Jeong, Shin Young
    Lee, Sang-Woo
    Lee, Jaetae
    Ahn, Byeong-Cheol
    ANNALS OF NUCLEAR MEDICINE, 2017, 31 (08) : 582 - 589
  • [44] I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal
    Chae Moon Hong
    Choon-Young Kim
    Seung Hyun Son
    Ji-hoon Jung
    Chang-Hee Lee
    Ju Hye Jeong
    Shin Young Jeong
    Sang-Woo Lee
    Jaetae Lee
    Byeong-Cheol Ahn
    Annals of Nuclear Medicine, 2017, 31 : 582 - 589
  • [45] Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH
    Fabian Pitoia
    Erika Abelleira
    Graciela Cross
    Endocrine, 2017, 55 : 200 - 208
  • [46] Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH
    Pitoia, Fabian
    Abelleira, Erika
    Cross, Graciela
    ENDOCRINE, 2017, 55 (01) : 209 - 217
  • [47] Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?
    Fabián Pitoia
    Osvaldo J. Degrossi
    Hugo Niepomniszcze
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 924 - 924
  • [48] Experience with recombinant human thyrotrophin in the management of differentiated thyroid cancer (DTC).
    Mariani, G
    Ferdeghini, M
    Augeri, C
    Villa, G
    Taddei, GZ
    Scopinaro, G
    Boni, G
    Bellina, CR
    Rabitti, C
    Molinari, E
    Bianchi, R
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 207P - 207P
  • [49] Radioidine kinetic after the administration of recombinant human TSH for thyroid cancer therapy
    Voliotopoulos, V.
    Antypas, C.
    Pantelis, E.
    Filou-Giougi, A.
    Valais, I.
    Stavraka-Kakavaki, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S332 - S332
  • [50] Radioiodinated recombinant human TSH: A novel radiopharmaceutical for thyroid cancer metastases detection
    Corsetti, F
    Chianelli, M
    Cornelissen, B
    Van de Wiele, C
    D'Alessandria, C
    Slegers, G
    Mather, SJ
    Di Mario, U
    Filetti, S
    Scopinaro, F
    Signore, A
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (01) : 57 - 63
12345